Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys

Efficacious interventions are urgently needed for the treatment of COVID-19. Here, we report a monoclonal antibody (mAb), MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor. Crosslinking of F...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuang, Peng, Yun, Wang, Rongjuan, Jiao, Shasha, Wang, Min, Huang, Weijin, Shan, Chao, Jiang, Wen, Li, Zepeng, Gu, Chunying, Chen, Ben, Hu, Xue, Yao, Yanfeng, Min, Juan, Zhang, Huajun, Chen, Ying, Gao, Ge, Tang, Peipei, Li, Gang, Wang, An, Wang, Lan, Zhang, Jinchao, Chen, Shuo, Gui, Xun, Yuan, Zhiming, Liu, Datao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666115/
https://www.ncbi.nlm.nih.gov/pubmed/33188207
http://dx.doi.org/10.1038/s41467-020-19568-1
_version_ 1783610069800189952
author Wang, Shuang
Peng, Yun
Wang, Rongjuan
Jiao, Shasha
Wang, Min
Huang, Weijin
Shan, Chao
Jiang, Wen
Li, Zepeng
Gu, Chunying
Chen, Ben
Hu, Xue
Yao, Yanfeng
Min, Juan
Zhang, Huajun
Chen, Ying
Gao, Ge
Tang, Peipei
Li, Gang
Wang, An
Wang, Lan
Zhang, Jinchao
Chen, Shuo
Gui, Xun
Yuan, Zhiming
Liu, Datao
author_facet Wang, Shuang
Peng, Yun
Wang, Rongjuan
Jiao, Shasha
Wang, Min
Huang, Weijin
Shan, Chao
Jiang, Wen
Li, Zepeng
Gu, Chunying
Chen, Ben
Hu, Xue
Yao, Yanfeng
Min, Juan
Zhang, Huajun
Chen, Ying
Gao, Ge
Tang, Peipei
Li, Gang
Wang, An
Wang, Lan
Zhang, Jinchao
Chen, Shuo
Gui, Xun
Yuan, Zhiming
Liu, Datao
author_sort Wang, Shuang
collection PubMed
description Efficacious interventions are urgently needed for the treatment of COVID-19. Here, we report a monoclonal antibody (mAb), MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor. Crosslinking of Fc with FcγRIIB mediates antibody-dependent enhancement (ADE) activity by MW05. This activity is eliminated by introducing the LALA mutation to the Fc region (MW05/LALA). Potent prophylactic and therapeutic effects against SARS-CoV-2 are observed in rhesus monkeys. A single dose of MW05/LALA blocks infection of SARS-CoV-2 in prophylactic treatment and clears SARS-CoV-2 in three days in a therapeutic treatment setting. These results pave the way for the development of MW05/LALA as an antiviral strategy for COVID-19.
format Online
Article
Text
id pubmed-7666115
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76661152020-11-17 Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys Wang, Shuang Peng, Yun Wang, Rongjuan Jiao, Shasha Wang, Min Huang, Weijin Shan, Chao Jiang, Wen Li, Zepeng Gu, Chunying Chen, Ben Hu, Xue Yao, Yanfeng Min, Juan Zhang, Huajun Chen, Ying Gao, Ge Tang, Peipei Li, Gang Wang, An Wang, Lan Zhang, Jinchao Chen, Shuo Gui, Xun Yuan, Zhiming Liu, Datao Nat Commun Article Efficacious interventions are urgently needed for the treatment of COVID-19. Here, we report a monoclonal antibody (mAb), MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor. Crosslinking of Fc with FcγRIIB mediates antibody-dependent enhancement (ADE) activity by MW05. This activity is eliminated by introducing the LALA mutation to the Fc region (MW05/LALA). Potent prophylactic and therapeutic effects against SARS-CoV-2 are observed in rhesus monkeys. A single dose of MW05/LALA blocks infection of SARS-CoV-2 in prophylactic treatment and clears SARS-CoV-2 in three days in a therapeutic treatment setting. These results pave the way for the development of MW05/LALA as an antiviral strategy for COVID-19. Nature Publishing Group UK 2020-11-13 /pmc/articles/PMC7666115/ /pubmed/33188207 http://dx.doi.org/10.1038/s41467-020-19568-1 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Wang, Shuang
Peng, Yun
Wang, Rongjuan
Jiao, Shasha
Wang, Min
Huang, Weijin
Shan, Chao
Jiang, Wen
Li, Zepeng
Gu, Chunying
Chen, Ben
Hu, Xue
Yao, Yanfeng
Min, Juan
Zhang, Huajun
Chen, Ying
Gao, Ge
Tang, Peipei
Li, Gang
Wang, An
Wang, Lan
Zhang, Jinchao
Chen, Shuo
Gui, Xun
Yuan, Zhiming
Liu, Datao
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
title Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
title_full Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
title_fullStr Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
title_full_unstemmed Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
title_short Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
title_sort characterization of neutralizing antibody with prophylactic and therapeutic efficacy against sars-cov-2 in rhesus monkeys
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666115/
https://www.ncbi.nlm.nih.gov/pubmed/33188207
http://dx.doi.org/10.1038/s41467-020-19568-1
work_keys_str_mv AT wangshuang characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT pengyun characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT wangrongjuan characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT jiaoshasha characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT wangmin characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT huangweijin characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT shanchao characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT jiangwen characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT lizepeng characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT guchunying characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT chenben characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT huxue characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT yaoyanfeng characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT minjuan characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT zhanghuajun characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT chenying characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT gaoge characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT tangpeipei characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT ligang characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT wangan characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT wanglan characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT zhangjinchao characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT chenshuo characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT guixun characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT yuanzhiming characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys
AT liudatao characterizationofneutralizingantibodywithprophylacticandtherapeuticefficacyagainstsarscov2inrhesusmonkeys

Ejemplares similares